

Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

<https://marketpublishers.com/r/E611EF77A7CEN.html>

Date: January 2018

Pages: 196

Price: US\$ 5,370.00 (Single User License)

ID: E611EF77A7CEN

Abstracts

T cell is a type of white blood cell, and plays an important role in cell-mediated immunity. Engineered T cells are genetically modified T cells, specifically altered for therapeutic actions against autoimmune diseases and various types of cancers. The engineered T cells are delivered into patient's body to reduce toxicity levels and restrict antigen escape (inability of immune system to respond to an infectious agent) for elimination of cancerous cells. The global engineered T cells market was valued at \$145.97 million in 2016, and is estimated to reach at \$2,124.02 million by 2023, registering a CAGR of 46.5% from 2017 to 2023.

Increase in of incidence of various types of cancers and autoimmune diseases is projected to drive the growth of the engineered T cells market. In addition, advantages offered by engineered T cells therapies over traditional cancer treatments such as chemotherapy, high technological advancements, and increase access to medical insurance are expected to boost the market growth. However, high cost associated with T cells therapies and lack of awareness about T cells therapies hinder the growth of this market.

The engineered T cells market is segmented based on type, application, end user, and geography. On the basis of type, the market is categorized into chimeric antigen receptor (CAR) modified T cells, tumor infiltrating lymphocytes (TIL), and T cells receptor (TCR) modified T cells. By application, it is classified into lung cancer, breast

cancer, colorectal cancer, melanoma, leukemia, and other applications. Depending on end user, it is fragmented into hospitals, cancer research centers, and clinics. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the global engineered T-cells market and the current trends and future estimations to elucidate the imminent investment pockets.

It presents a quantitative analysis of the market from 2016 to 2023 to enable stakeholders to capitalize on the prevailing market opportunities.

Extensive analysis of the market based on end user assists to understand the trends in the industry.

Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Type

Chimeric Antigen Receptor (CAR)

Tumor Infiltrating Lymphocytes (TIL)

T-cell Receptor (TCR)

By Application

Lung Cancer

Breast Cancer

Colorectal Cancer

Melanoma

Leukemia

Others

By End User

Hospitals

Cancer Research Centers

Clinics

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

France

UK

Italy

Spain

Rest of Europe

Asia-Pacific

Japan

China

Australia

India

South Korea

Taiwan

Rest of Asia-Pacific

LAMEA

Brazil

Turkey

Saudi Arabia

South Africa

Rest of LAMEA

KEY PLAYERS PROFILED IN THE REPORT

Autolus Limited

Bellicum Pharmaceuticals, Inc.

Cell Medica

Eli Lilly and Company

Gilead Sciences, Inc. Juno Therapeutics

Novartis AG

Oxford Biomedica

Pfizer Inc.

Precision Bioscience

The other players in the value chain include (profiles not included in the report)

Redmile Group

Seeking Alpha

Unum Therapeutics Inc.

Contents

CHAPTER 1 INTRODUCTION

- 1.1. REPORT DESCRIPTION
- 1.2. KEY BENEFITS FOR STAKEHOLDERS
- 1.3. KEY MARKET SEGMENTS
- 1.4. RESEARCH METHODOLOGY
 - 1.4.1. Secondary research
 - 1.4.2. Primary research
 - 1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

- 2.1. KEY FINDINGS OF THE STUDY
- 2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

- 3.1. MARKET DEFINITION AND SCOPE
- 3.2. KEY FINDINGS
 - 3.2.1. Top investment pockets
 - 3.2.2. Top winning strategies
 - 3.2.2.1. TOP WINNING STRATEGIES, BY YEAR, 2015-2017
 - 3.2.2.2. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015-2017 (%)
 - 3.2.2.3. TOP WINNING STRATEGIES, BY COMPANY, 2015-2017
- 3.3. PORTERS FIVE FORCES ANALYSIS
 - 3.3.1. Bargaining power of buyers
 - 3.3.2. Bargaining power of suppliers
 - 3.3.3. Threat of substitutes
 - 3.3.4. Threat of new entrants
 - 3.3.5. Competitive rivalry
- 3.4. TOP PLAYER POSITIONING, 2016
- 3.5. MARKET DYNAMICS
 - 3.5.1. Drivers
 - 3.5.1.1. Increase in government expenditure for the healthcare sector
 - 3.5.1.2. Increased access to medical insurance
 - 3.5.1.3. Increase in geriatric population
 - 3.5.1.4. Increase in prevalence of cancer diseases

3.5.2. Restraint

3.5.2.1. Risk of allergic reaction and limitations of the engineered T cells treatment

3.5.2.2. Stringent government regulations

3.5.2.3. High cost of engineered T cells treatment

3.5.3. Opportunity

3.5.3.1. Increase in R&D in engineered T cells

3.5.3.2. Lucrative opportunities from emerging economies

CHAPTER 4 ENGINEERED T CELLS MARKET, BY TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. CHIMERIC ANTIGEN RECEPTOR (CAR) MODIFIED T CELLS

4.2.1. Key market trends and opportunities

4.2.2. Market size and forecast

4.3. T CELLS RECEPTOR (TCR) MODIFIED T CELLS

4.3.1. Key market trends and opportunities

4.3.2. Market size and forecast

4.4. TUMOR INFILTRATING LYMPHOCYTES

4.4.1. Key market trends and opportunities

4.4.2. Market size and forecast

CHAPTER 5 ENGINEERED T CELLS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LUNG CANCER

5.2.1. Market size and forecast

5.3. BREAST CANCER

5.3.1. Market size and forecast

5.4. COLORECTAL CANCER

5.4.1. Market size and forecast

5.5. MELANOMA

5.5.1. Market size and forecast

5.6. LEUKEMIA

5.6.1. Market size and forecast

5.7. OTHERS APPLICATIONS

5.7.1. Market size and forecast

CHAPTER 6 ENGINEERED T CELLS MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. CANCER RESEARCH CENTERS

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

CHAPTER 7 ENGINEERED T CELLS MARKET, BY REGION

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends and opportunities

7.2.2. Market size and forecast

7.2.3. U.S. market size and forecast

7.2.4. Canada market size and forecast

7.2.5. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends and opportunities

7.3.2. Market size and forecast

7.3.3. Germany market size and forecast

7.3.4. France market size and forecast

7.3.5. UK market size and forecast

7.3.6. Italy market size and forecast

7.3.7. Spain market size and forecast

7.3.8. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends and opportunities

7.4.2. Market size and forecast

7.4.3. Japan market size and forecast

7.4.4. China market size and forecast

7.4.5. India market size and forecast

7.4.6. Australia market size and forecast

7.4.7. South Korea market size and forecast

7.4.8. Taiwan market size and forecast

7.4.9. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends and opportunities

7.5.2. Market size and forecast

7.5.3. Brazil market size and forecast

7.5.4. Turkey market size and forecast

7.5.5. Saudi Arabia market size and forecast

7.5.6. South Africa market size and forecast

7.5.7. Rest of LAMEA market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. AUTOLUS LIMITED

8.1.1. Company overview

8.1.2. Company snapshot

8.2. BELLICUM PHARMACEUTICALS, INC.

8.2.1. Company overview

8.2.2. Company snapshot

8.2.3. Clinical trials

8.2.4. Business performance

8.2.5. Key strategic moves and developments

8.3. CELL MEDICA LIMITED

8.3.1. Company overview

8.3.2. Company snapshot

8.3.3. Operating business segments

8.3.4. Clinical trials

8.3.5. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY

8.4.1. Company overview

8.4.2. Company snapshot

8.4.3. Operating business segments

8.4.4. Clinical trials

8.4.5. Business performance

8.4.6. Key strategic moves and developments

8.5. GILEAD SCIENCES, INC. (KITE PHARMA INC.)

8.5.1. Company overview

8.5.2. Company snapshot

8.5.3. Operating business segments

8.5.4. Clinical trials

8.5.5. Business performance

8.6. JUNO THERAPEUTICS, INC.

8.6.1. Company overview

8.6.2. Company snapshot

8.6.3. Clinical trials

8.6.4. Business performance

8.6.5. Key strategic moves and developments

8.7. NOVARTIS AG

8.7.1. Company overview

8.7.2. Company snapshot

8.7.3. Operating business segments

8.7.4. Clinical trials

8.7.5. Business performance

8.8. OXFORD BIOMEDICA PLC

8.8.1. Company overview

8.8.2. Company snapshot

8.8.3. Operating business segments

8.8.4. Clinical trials

8.8.5. Business performance

8.9. PFIZER INC.

8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Clinical trials

8.9.5. Business performance

8.10. PRECISION BIOSCIENCES INC.

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Key strategic moves and developments

List Of Tables

LIST OF TABLES

TABLE 1. PROBABILITY OF DEVELOPING INVASIVE CANCER DURING SELECTED AGE GROUPS (%)

TABLE 2. MEDIAN MONTHLY PRICE OF GENERIC AND BRANDED CANCER MEDICINES

TABLE 3. GLOBAL ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 4. ENGINEERED T CELLS MARKET FOR CAR MODIFIED T CELLS, BY REGION, 2014-2022 (\$MILLION)

TABLE 5. ENGINEERED T CELLS MARKET FOR TCR MODIFIED T CELLS, BY REGION, 2014-2022 (\$MILLION)

TABLE 6. ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY REGION, 2014-2022 (\$MILLION)

TABLE 7. GLOBAL ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 8. ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY REGION, 2014-2022 (\$MILLION)

TABLE 9. ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY REGION, 2014-2022 (\$MILLION)

TABLE 10. ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY REGION, 2014-2022 (\$MILLION)

TABLE 11. ENGINEERED T CELLS MARKET FOR MELANOMA, BY REGION, 2014-2022 (\$MILLION)

TABLE 12. ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY REGION, 2014-2022 (\$MILLION)

TABLE 13. ENGINEERED T CELLS MARKET FOR OTHER APPLICATIONS, BY REGION, 2014-2022 (\$MILLION)

TABLE 14. GLOBAL ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 15. ENGINEERED T CELLS MARKET FOR HOSPITALS, BY REGION, 2014-2022 (\$MILLION)

TABLE 16. ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY REGION, 2014-2022 (\$MILLION)

TABLE 17. ENGINEERED T CELLS MARKET FOR CLINICS, BY REGION, 2014-2022 (\$MILLION)

TABLE 18. ENGINEERED T CELLS MARKET, BY REGION, 2016-2023 (\$MILLION)

TABLE 19. NORTH AMERICA ENGINEERED T CELLS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 20. NORTH AMERICA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 21. NORTH AMERICA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 22. NORTH AMERICA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 23. U.S. ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 24. U.S. ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 25. U.S. ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 26. CANADA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 27. CANADA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 28. CANADA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 29. MEXICO ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 30. MEXICO ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 31. MEXICO ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 32. EUROPEAN ENGINEERED T CELLS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 33. EUROPEAN ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 34. EUROPEAN ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 35. EUROPEAN ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 36. GERMANY ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 37. GERMANY ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 38. GERMANY ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 39. FRANCE ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023
(\$MILLION)

TABLE 40. FRANCE ENGINEERED T CELLS MARKET, BY APPLICATION,
2016-2023 (\$MILLION)

TABLE 41. FRANCE ENGINEERED T CELLS MARKET, BY END USER, 2016-2023
(\$MILLION)

TABLE 42. UK ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 43. UK ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023
(\$MILLION)

TABLE 44. UK ENGINEERED T CELLS MARKET, BY END USER, 2016-2023
(\$MILLION)

TABLE 45. ITALY ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023
(\$MILLION)

TABLE 46. ITALY ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023
(\$MILLION)

TABLE 47. ITALY ENGINEERED T CELLS MARKET, BY END USER, 2016-2023
(\$MILLION)

TABLE 48. SPAIN ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023
(\$MILLION)

TABLE 49. SPAIN ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023
(\$MILLION)

TABLE 50. SPAIN ENGINEERED T CELLS MARKET, BY END USER, 2016-2023
(\$MILLION)

TABLE 51. REST OF EUROPE ENGINEERED T CELLS MARKET, BY TYPE,
2016-2023 (\$MILLION)

TABLE 52. REST OF EUROPE ENGINEERED T CELLS MARKET, BY APPLICATION,
2016-2023 (\$MILLION)

TABLE 53. REST OF EUROPE ENGINEERED T CELLS MARKET, BY END USER,
2016-2023 (\$MILLION)

TABLE 54. ASIA-PACIFIC ENGINEERED T CELLS MARKET, BY COUNTRY,
2016-2023 (\$MILLION)

TABLE 55. ASIA-PACIFIC ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023
(\$MILLION)

TABLE 56. ASIA-PACIFIC ENGINEERED T CELLS MARKET, BY APPLICATION,
2016-2023 (\$MILLION)

TABLE 57. ASIA-PACIFIC ENGINEERED T CELLS MARKET, BY END-USER,
2016-2023 (\$MILLION)

TABLE 58. JAPAN ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023
(\$MILLION)

TABLE 59. JAPAN ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 60. JAPAN ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 61. CHINA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 62. CHINA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 63. CHINA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 64. INDIA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 65. INDIA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 66. INDIA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 67. AUSTRALIA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 68. AUSTRALIA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 69. AUSTRALIA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 70. SOUTH KOREA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 71. SOUTH KOREA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 72. SOUTH KOREA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 73. TAIWAN ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 74. TAIWAN ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 75. TAIWAN ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 76. REST OF ASIA-APCIFIC ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 77. REST OF ASIA-APCIFIC ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 78. REST OF ASIA-APCIFIC ENGINEERED T CELLS MARKET, BY END

USER, 2016-2023 (\$MILLION)

TABLE 79. LAMEA ENGINEERED T CELLS MARKET, BY COUNTRY, 2016-2023 (\$MILLION)

TABLE 80. LAMEA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 81. LAMEA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 82. LAMEA ENGINEERED T CELLS MARKET, BY END-USER, 2016-2023 (\$MILLION)

TABLE 83. BRAZIL ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 84. BRAZIL ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 85. BRAZIL ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 86. TURKEY ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 87. TURKEY ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 88. TURKEY ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 89. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 90. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 91. SAUDI ARABIA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 92. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 93. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 94. SOUTH AFRICA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 95. REST OF LAMEA ENGINEERED T CELLS MARKET, BY TYPE, 2016-2023 (\$MILLION)

TABLE 96. REST OF LAMEA ENGINEERED T CELLS MARKET, BY APPLICATION, 2016-2023 (\$MILLION)

TABLE 97. REST OF LAMEA ENGINEERED T CELLS MARKET, BY END USER, 2016-2023 (\$MILLION)

TABLE 98. AUTOLUS LIMITED: COMPANY SNAPSHOT
TABLE 99. BELLICUM PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 100. BELLICUM PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 101. CELL MEDICA LIMITED: COMPANY SNAPSHOT
TABLE 102. CELL MEDICA LIMITED: OPERATING SEGMENTS
TABLE 103. CELL MEDICA LIMITED: PRODUCT PORTFOLIO
TABLE 104. LILLY: COMPANY SNAPSHOT
TABLE 105. LILLY: OPERATING SEGMENTS
TABLE 106. GILEAD SCIENCE INC.: COMPANY SNAPSHOT
TABLE 107. GILEAD SCIENCE INC.: OPERATING SEGMENTS
TABLE 108. GILEAD SCIENCE, INC.: PRODUCT PORTFOLIO
TABLE 109. JUNO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 110. JUNO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 111. NOVARTIS: COMPANY SNAPSHOT
TABLE 112. NOVARTIS: OPERATING SEGMENTS
TABLE 113. NOVARTIS: PRODUCT PORTFOLIO
TABLE 114. KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. OXFORD BIOMEDICA: COMPANY SNAPSHOT
TABLE 116. OXFORD BIOMEDICA: OPERATING SEGMENTS
TABLE 117. OXFORD BIOMEDICA: PRODUCT PORTFOLIO
TABLE 118. PFIZER: COMPANY SNAPSHOT
TABLE 119. PFIZER: OPERATING SEGMENTS
TABLE 120. PFIZER: PRODUCT PORTFOLIO
TABLE 121. PRECISION BIOSCIENCES: COMPANY SNAPSHOT
TABLE 122. PRECISION BIOSCIENCES: OPERATING SEGMENT

List Of Figures

LIST OF FIGURES

FIGURE 1. MARKET SEGMENTATION

FIGURE 2. TOP INVESTMENT POCKETS

FIGURE 3. TOP PLAYER POSITIONING: ENGINEERED T CELLS MARKET, 2016

FIGURE 4. PERCENTAGE OF GOVERNMENT EXPENDITURE ON HEALTHCARE, 2013-2014

FIGURE 5. PERCENTAGE DISTRIBUTION OF POPULATION AGED 65 YEARS AND ABOVE BY REGION: 2015, 2030 AND 2050

FIGURE 6. ESTIMATED NUMBER OF DEATHS DUE TO CANCER, U.S., 2015 AND 2017

FIGURE 7. REIMBURSEMENT STATUS OF CANCER MEDICINES APPROVED IN 2014 AND 2015

FIGURE 8. ENGINEERING PROCESS FOR CAR MODIFIED T CELLS

FIGURE 9. ENGINEERED T CELLS MARKET FOR CAR MODIFIED T CELLS, BY COUNTRY, 2016 (%)

FIGURE 10. ENGINEERED T CELLS MARKET FOR TCR MODIFIED T CELLS, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 11. ENGINEERED T CELLS MARKET FOR TUMOR INFILTRATING LYMPHOCYTES, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 12. ENGINEERED T CELLS MARKET FOR LUNG CANCER, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 13. ENGINEERED T CELLS MARKET FOR BREAST CANCER, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 14. ENGINEERED T CELLS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 15. ENGINEERED T CELLS MARKET FOR MELANOMA, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 16. ENGINEERED T CELLS MARKET FOR LEUKEMIA, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 17. ENGINEERED T CELLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 18. ENGINEERED T CELLS MARKET FOR HOSPITALS, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 19. ENGINEERED T CELLS MARKET FOR CANCER RESEARCH CENTERS, BY COUNTRY, 2016-2023 (\$MILLION)

FIGURE 20. ENGINEERED T CELLS MARKET FOR CLINICS, BY COUNTRY,

2016-2023 (\$MILLION)

FIGURE 21. U.S. ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 22. CANADA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 23. MEXICO ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 24. GERMANY ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 25. FRANCE ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 26. UK ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 27. ITALY ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 28. SPAIN ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 29. REST OF EUROPE ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 30. JAPAN ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 31. CHINA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 32. INDIA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 33. AUSTRALIA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 34. SOUTH KOREA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 35. TAIWAN ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 36. REST OF ASIA-PACIFIC ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 37. BRAZIL ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 38. TURKEY ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 39. SAUDI ARABIA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 40. SOUTH AFRICA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 41. REST OF LAMEA ENGINEERED T CELLS MARKET, 2016-2023 (\$MILLION)

FIGURE 42. BELLICUM PHARMACEUTICALS: NET SALES, 2014-2016 (\$MILLION)

FIGURE 43. LILLY: NET SALES, 2014-2016 (\$MILLION)

FIGURE 44. LILLY: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 45. LILLY: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 46. GILEAD SCIENCE INC.: NET SALES, 2014-2016 (\$MILLION)

FIGURE 47. GILEAD SCIENCE INC.: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 48. GILEAD SCIENCE INC.: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 49. JUNO THERAPEUTICS, INC.: NET SALES, 2014-2016 (\$MILLION)

FIGURE 50. NOVARTIS: NET SALES, 2014-2016 (\$MILLION)

FIGURE 51. NOVARTIS: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 52. NOVARTIS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 53. OXFORD BIOMEDICA: NET SALES, 2014-2016 (\$MILLION)

FIGURE 54. OXFORD BIOMEDICA: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 55. OXFORD BIOMEDICA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

FIGURE 56. PFIZER: NET SALES, 2014-2016 (\$MILLION)

FIGURE 57. PFIZER: REVENUE SHARE BY SEGMENT, 2016 (%)

FIGURE 58. PFIZER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

I would like to order

Product name: Engineered T Cells Market by Type (Tumor Infiltrating Lymphocytes, T Cell Receptor, and Chimeric Antigen Receptor), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Leukemia, and Others), and End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2017-2023

Product link: <https://marketpublishers.com/r/E611EF77A7CEN.html>

Price: US\$ 5,370.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E611EF77A7CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970